A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER-2 Positive Breast Cancer
Interventions: DRUG: Liposomal doxorubicin|DRUG: Docetaxel|DRUG: Trastuzumab|DRUG: Metformin
Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori